Citations 1
Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
Cowan, Andrew J. , Leleu, Xavier , Medvedova, Eva , Costello, Caitlin, Hillengass, Jens, Mawad, Raya, Schade, Henning, Giles, Daniel Morillo, Yaron, Yifah, Ng, Patrick P., Madan, Sumit , Abdallah, Al-Ola , Touzeau, Cyrille , Lipe, Brea , Costello, Caitlin , Bergsagel, P. Leif , Oriol, Albert
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7284-7285
